High-flow nasal oxygen may cost less than NIV in patients with acute respiratory failure, but not in patients critically ill with COVID-19.

When assessing intubation/death at 7 days in hospitalized adults with acute respiratory failure, high-flow nasal oxygen was generally noninferior to noninvasive ventilation, according to results ...

A large multicenter, randomized clinical trial revealed no difference in the risk of endotracheal intubation requirement at 30 days between awake prone positioning and standard positioning for ...

It is defined by acute hypoxemia, bilateral infiltrates on chest imaging, and non-cardiogenic pulmonary edema, and it remains a heterogeneous condition with mortality rates stubbornly close to 40%.